Titan Biotech's Q1 FY 2026-27 Quarterly Results

Result Summary

• Titan Biotech Ltd reported a 19.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 29.1%.
• Its expenses for the quarter were up by 18.7% QoQ and 23.4% YoY.
• The net profit increased 61.4% QoQ and increased 58.3% YoY.
• The earnings per share (EPS) of Titan Biotech Ltd stood at 2.63 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Titan Biotech Ltd is a company that operates in the biotechnology sector, serving industries that require specialized products related to biological and biomedical applications. The company's main products or services typically include the manufacture and supply of biological products such as culture media, plant tissue culture media, and other related items. These products are crucial for research, development, and production processes in various scientific and medical fields. Information about any recent major developments is not available within the provided data set, hence no further details can be provided regarding recent activities or changes within the company.

Revenue

In the first quarter of FY27, Titan Biotech Ltd reported a total income of ₹60.98 crores. This represents a significant increase compared to both the previous quarter (Q4FY26), which recorded total income of ₹50.94 crores, and the same quarter in the previous year (Q1FY26), which had a total income of ₹47.22 crores. Year-over-year, this marks a growth rate of 29.1%, while quarter-over-quarter, the increase was 19.7%. The substantial rise in total income over these periods indicates a positive trend in revenue generation for the company in the current fiscal year.

Profitability

The company's profit before tax for Q1FY27 was ₹12.73 crores, showing a substantial growth from ₹10.28 crores in Q4FY26 and ₹8.11 crores in Q1FY26. This reflects a 23.8% increase quarter-over-quarter and a 57.0% increase year-over-year. After accounting for taxes, the profit after tax stood at ₹10.86 crores in Q1FY27, which is a noteworthy rise from ₹6.73 crores in the preceding quarter and ₹6.86 crores in the comparable quarter of the previous year. The growth rates for profit after tax were 61.4% QoQ and 58.3% YoY, indicating robust profitability improvements. The tax expense for Q1FY27 was ₹3.28 crores, decreasing by 12.1% from the previous quarter but increasing by 68.2% from Q1FY26.

Operating Metrics

During Q1FY27, the total expenses incurred by Titan Biotech Ltd amounted to ₹48.25 crores, which is up from ₹40.66 crores in Q4FY26 and ₹39.11 crores in Q1FY26. The expenses increased by 18.7% quarter-over-quarter and 23.4% year-over-year. The earnings per share (EPS) for the quarter was ₹2.63, showing a growth of 61.3% from the previous quarter's EPS of ₹1.63. However, compared to the same quarter in the previous year, where EPS was ₹8.30, there is a decline of 68.3%. This disparity in EPS YoY is noteworthy despite the increase in profitability and total income, suggesting changes in share distribution or other factors not disclosed in the provided data.